MA33993B1 - Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r) - Google Patents

Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r)

Info

Publication number
MA33993B1
MA33993B1 MA35130A MA35130A MA33993B1 MA 33993 B1 MA33993 B1 MA 33993B1 MA 35130 A MA35130 A MA 35130A MA 35130 A MA35130 A MA 35130A MA 33993 B1 MA33993 B1 MA 33993B1
Authority
MA
Morocco
Prior art keywords
reception
antibodies against
formulations containing
containing antibodies
stable formulations
Prior art date
Application number
MA35130A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel B Dix
Kenneth S Graham
Douglas E Kamen
Scott M Walsh
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44258720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33993(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA33993B1 publication Critical patent/MA33993B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/065—Rigid ampoules, e.g. glass ampoules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a pour objet des formulations pharmaceutiques comprenant un anticorps humain qui se lie spécifiquement au récepteur humain de l'interleukine-6 (hll-6r). Les formulations peuvent contenir, en plus d'un anticorps anti-hll-6r, au moins un acide aminé, au moins un sucre, et/ou au moins un agent tensioactif non ionique. Les formulations pharmaceutiques selon la présente invention présentent un degré sensible de la stabilité des anticorps après un stockage pendant plusieurs mois.
MA35130A 2010-01-08 2011-01-07 Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r) MA33993B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29322710P 2010-01-08 2010-01-08
US12/986,223 US9173880B2 (en) 2010-01-08 2011-01-07 Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
PCT/US2011/020457 WO2011085158A2 (fr) 2010-01-08 2011-01-07 Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r)

Publications (1)

Publication Number Publication Date
MA33993B1 true MA33993B1 (fr) 2013-02-01

Family

ID=44258720

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35130A MA33993B1 (fr) 2010-01-08 2011-01-07 Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r)

Country Status (43)

Country Link
US (5) US9173880B2 (fr)
EP (5) EP4588938A3 (fr)
JP (2) JP5805660B2 (fr)
KR (1) KR101787351B1 (fr)
CN (1) CN102869346B (fr)
AR (1) AR079836A1 (fr)
AU (1) AU2011204311B2 (fr)
BR (1) BR112012016618A2 (fr)
CA (1) CA2790197C (fr)
CL (1) CL2012001853A1 (fr)
CO (1) CO6592078A2 (fr)
CR (1) CR20120393A (fr)
CY (2) CY1121420T1 (fr)
DK (4) DK2521536T3 (fr)
DO (1) DOP2012000193A (fr)
EC (1) ECSP12012092A (fr)
ES (4) ES3040609T3 (fr)
FI (1) FI4098247T3 (fr)
GT (1) GT201200223A (fr)
HR (4) HRP20221139T1 (fr)
HU (4) HUE073279T2 (fr)
JO (1) JO3417B1 (fr)
LT (4) LT3756652T (fr)
MA (1) MA33993B1 (fr)
MX (1) MX2012007794A (fr)
MY (1) MY156702A (fr)
NI (1) NI201200119A (fr)
NZ (1) NZ601114A (fr)
PE (2) PE20121687A1 (fr)
PH (1) PH12012501370B1 (fr)
PL (4) PL3756652T3 (fr)
PT (4) PT4098247T (fr)
PY (1) PY1100365A (fr)
RS (4) RS57903B1 (fr)
RU (1) RU2554779C2 (fr)
SG (1) SG182283A1 (fr)
SI (4) SI3409269T1 (fr)
SM (4) SMT202500337T1 (fr)
TW (2) TWI587870B (fr)
UA (1) UA107211C2 (fr)
UY (1) UY33169A (fr)
WO (1) WO2011085158A2 (fr)
ZA (1) ZA201205035B (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
CA2825778A1 (fr) 2011-01-28 2012-08-02 Sanofi Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
KR20200039028A (ko) * 2011-10-11 2020-04-14 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
PT2830658T (pt) * 2012-03-26 2018-12-28 Sanofi Sa Formulações de agente de ligação igg4 estável
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (fr) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de la polyarthrite rhumatoïde par l'administration d'un anticorps anti il-6r
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (fr) 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions et procédés pour le traitement de la polyarthrite rhumatoïde
WO2018039499A1 (fr) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Modification de protéines de cellules hôtes
BR112019005328A2 (pt) 2016-09-27 2019-06-18 Fresenius Kabi Deutschland Gmbh composição farmacêutica líquida
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
WO2018081755A1 (fr) * 2016-10-29 2018-05-03 University Of Miami Anticorps contre le virus zika
BR112019006853B1 (pt) 2016-10-31 2021-08-24 Fresenius Kabi Deutschland Gmbh Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo
BR112019011900A2 (pt) * 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
CA3055583A1 (fr) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injecteur
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
MX2020005630A (es) * 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
CA3085177A1 (fr) 2018-01-31 2019-08-08 Regeneron Pharamaceuticals, Inc. Systemes et procedes permettant de caracteriser des impuretes de produit medicamenteux
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
AU2019227531B2 (en) 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
WO2020047067A1 (fr) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Procédés de caractérisation de complexes protéiques
WO2020088346A1 (fr) * 2018-10-31 2020-05-07 Mycenax Biotech Inc. Formulations pharmaceutiques aqueuses
JP2022517720A (ja) 2019-01-16 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ジスルフィド結合を特徴付けるための方法
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
JP7541534B2 (ja) 2019-05-13 2024-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
KR20260058863A (ko) 2019-09-24 2026-04-29 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CA3165060C (fr) 2020-01-21 2023-06-20 Yiming Zhao Procedes de deglycosylation pour l'electrophorese de proteines glycosylees
WO2021163549A1 (fr) 2020-02-14 2021-08-19 Sanofi Biotechnology Compositions et méthodes de traitement d'infections virales
CA3180369A1 (fr) 2020-05-26 2021-12-02 Inka Albrecht Compositions comprenant un anticorps dirige contre le recepteur de l'interleukine 6 pour le traitement de la polyarthrite rhumatoide et procedes d'utilisation associes
US20230192871A1 (en) 2020-05-29 2023-06-22 Sanofi Biotechnology Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
CA3185091A1 (fr) * 2020-07-08 2022-01-13 Yuan Cheng Formulations stabilisees contenant des anticorps anti-ctla-4
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
KR20220028972A (ko) * 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
WO2022102768A1 (fr) * 2020-11-16 2022-05-19 アステラス製薬株式会社 Anticorps bispécifique anti-tspan8-anti-cd3 et anticorps anti-tspan8
EP4251128A1 (fr) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Formulations à libération prolongée à l'aide d'une émulsification par membrane non aqueuse
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
TW202246325A (zh) 2021-03-03 2022-12-01 美商再生元醫藥公司 用於定量及修飾蛋白質黏度之系統及方法
EP4315344A1 (fr) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Procédés et systèmes pour développer des protocoles de mélange
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2023020563A1 (fr) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Formulations liquides comprenant des anticorps humanisés à concentrations élevées pour le traitement de maladies liées à l'il-6
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
EP4413364A2 (fr) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systèmes et méthodes de modélisation et de régulation du ph
EP4413359A1 (fr) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Étalonnage et correction de ph-mètre
WO2023076340A1 (fr) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de génération d'eau de laboratoire et de distribution d'eau de laboratoire à différentes températures
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
EP4493921A1 (fr) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Procédés et systèmes permettant d'analyser des variants polypeptidiques
EP4634659A1 (fr) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Procédés et systèmes d'évaluation de l'intégrité d'une colonne chromatographique
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
EP4669963A2 (fr) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. Paramètres d'adéquation de système et vieillissement de colonne
JP2026514305A (ja) 2023-05-01 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品
WO2024259313A1 (fr) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Emballage de dispositif médical et procédés associés
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
EP4780828A2 (fr) 2023-09-18 2026-07-29 Regeneron Pharmaceuticals, Inc. Procédés et systèmes pour développer des protocoles de chromatographie
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
CN122138969A (zh) 2023-10-18 2026-06-02 瑞泽恩制药公司 从过程中上游细胞培养物材料中快速纯化单克隆抗体
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
TW202547482A (zh) 2024-01-12 2025-12-16 法商賽諾菲生物技術公司 已接受類固醇之具有風濕性多肌痛症之個體之治療
WO2025166281A1 (fr) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Plateforme d'analyse par spectrométrie de masse à détection de charge d'aavs
TW202600593A (zh) 2024-02-16 2026-01-01 美商再生元醫藥公司 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
WO2025259840A1 (fr) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Procédés et systèmes de chromatographie mise à l'échelle
TW202617180A (zh) * 2024-06-20 2026-05-01 南韓商賽特瑞恩股份有限公司 穩定的藥學製劑
WO2026025028A1 (fr) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Procédés de fabrication de formulations protéiques à concentration ultra-élevée par lyophilisation
WO2026060350A1 (fr) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Procédés d'amélioration de la photostabilité et de contrôle de la formation d'espèces hmw dans des formulations biologiques, et formulations biologiques produites par les procédés
WO2026076201A2 (fr) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de production de protéines thérapeutiques par filtration tangentielle à passage unique pour la concentration en ligne et la réduction volumique de groupes de production
WO2026080597A1 (fr) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Administration prolongée de produits biologiques et fabrication non aqueuse de ceux-ci
WO2026112457A2 (fr) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène hétérodimères qui se lient à des particules virales et leurs utilisations
WO2026136650A1 (fr) 2024-12-20 2026-06-25 Regeneron Pharmaceuticals, Inc. Programme fixe de chaîne d'ensemencement pour améliorer la production de protéines
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007208A (en) 1911-07-21 1911-10-31 Axel W Johnson Window.
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) * 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
AU687763B2 (en) 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (fr) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System Anticorps monoclonaux diriges contre le recepteur de l'il-6 humaine
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US6086874A (en) 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
US6261560B1 (en) 1995-02-13 2001-07-17 Chugai Seiyaku Kabushiki Kaisha Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
KR20040024561A (ko) 1997-08-15 2004-03-20 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
ATE383875T1 (de) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
CA2341239C (fr) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Agent preventif ou therapeutique de la pancreatite comprenant un antagoniste de l'il-6 en tant qu'ingredient actif
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
EP1224189B1 (fr) 1999-10-07 2006-01-25 Eli Lilly And Company Derives de dihydroquinolone condenses permettant d'inhiber la mrp1
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2539061A1 (fr) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg Utilisation d'un agoniste de l'il-6 pour le traitement de maladies mediees par l'il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
CA2555688C (fr) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methodes de traitement de l'osteoarthrose avec des antagonistes de l'interleukine-6
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JPWO2006046661A1 (ja) 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−６阻害剤
EP1828250A2 (fr) 2004-12-16 2007-09-05 Genentech, Inc. Procedes de traitement de troubles auto-immuns
KR20080071192A (ko) 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
WO2008049897A1 (fr) 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de protéines
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2244814B1 (fr) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Formulation de vwf recombinant
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
WO2009109584A1 (fr) 2008-03-07 2009-09-11 Ferring International Center S. A. Anticorps qui ne se lie qu'au complexe il6-sil6r
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RU2565809C2 (ru) * 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
KR20230155586A (ko) 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
JP7101479B2 (ja) 2014-09-16 2022-07-15 サノフィ・バイオテクノロジー 関節リウマチ患者の健康に関連した生活の質を改善するための組成物
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR20230093522A (ko) 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
HUE073279T2 (hu) 2026-01-28
EP4098247A1 (fr) 2022-12-07
TWI533884B (zh) 2016-05-21
ES3040609T3 (en) 2025-11-03
EP3756652B1 (fr) 2022-06-22
DK2521536T3 (en) 2018-11-19
EP3409269B1 (fr) 2020-08-12
PT3409269T (pt) 2020-09-03
ECSP12012092A (es) 2012-09-28
TWI587870B (zh) 2017-06-21
US20110171241A1 (en) 2011-07-14
HRP20221139T1 (hr) 2022-12-09
CL2012001853A1 (es) 2012-11-30
CY1123909T1 (el) 2022-03-24
JP2016020371A (ja) 2016-02-04
CR20120393A (es) 2012-10-30
JP2013516481A (ja) 2013-05-13
LT3756652T (lt) 2022-09-12
EP4588938A3 (fr) 2025-10-29
SMT202200365T1 (it) 2022-11-18
HUE051115T2 (hu) 2021-01-28
PT3756652T (pt) 2022-08-24
PL2521536T3 (pl) 2019-01-31
HUE040403T2 (hu) 2019-03-28
EP3409269A1 (fr) 2018-12-05
RS61045B1 (sr) 2020-12-31
DK3756652T3 (da) 2022-09-12
LT3409269T (lt) 2020-10-12
EP4098247B1 (fr) 2025-08-20
CN102869346B (zh) 2014-11-12
AR079836A1 (es) 2012-02-22
CA2790197A1 (fr) 2011-07-14
HUE059811T2 (hu) 2022-12-28
GT201200223A (es) 2013-11-18
EP3756652A1 (fr) 2020-12-30
MX2012007794A (es) 2012-08-01
NI201200119A (es) 2013-01-24
US11098127B2 (en) 2021-08-24
EP4588938A2 (fr) 2025-07-23
SI4098247T1 (sl) 2025-10-30
SI3756652T1 (sl) 2022-10-28
DOP2012000193A (es) 2012-09-30
CA2790197C (fr) 2017-12-12
ES2925665T3 (es) 2022-10-19
BR112012016618A2 (pt) 2020-06-02
JP6053886B2 (ja) 2016-12-27
AU2011204311B2 (en) 2014-05-08
PL4098247T3 (pl) 2025-10-20
ZA201205035B (en) 2013-02-27
NZ601114A (en) 2014-03-28
WO2011085158A3 (fr) 2012-03-22
PH12012501370A1 (en) 2012-10-22
RS63567B1 (sr) 2022-10-31
HRP20201428T1 (hr) 2020-11-27
PE20170948A1 (es) 2017-07-13
PY1100365A (es) 2015-06-01
KR101787351B1 (ko) 2017-10-19
HRP20181821T1 (hr) 2018-12-28
TW201141518A (en) 2011-12-01
US20160002341A1 (en) 2016-01-07
AU2011204311A1 (en) 2012-08-02
MY156702A (en) 2016-03-15
SG182283A1 (en) 2012-08-30
US12077593B2 (en) 2024-09-03
PH12012501370B1 (en) 2019-10-16
RS57903B1 (sr) 2019-01-31
SMT201800673T1 (it) 2019-01-11
HRP20251207T1 (hr) 2025-12-05
EP2521536A2 (fr) 2012-11-14
SMT202000577T1 (it) 2020-11-10
US20250197515A1 (en) 2025-06-19
PL3409269T3 (pl) 2020-12-14
JP5805660B2 (ja) 2015-11-04
KR20120133376A (ko) 2012-12-10
US9173880B2 (en) 2015-11-03
RS67230B1 (sr) 2025-10-31
UA107211C2 (uk) 2014-12-10
US10072086B2 (en) 2018-09-11
ES2818992T3 (es) 2021-04-14
ES2688070T3 (es) 2018-10-30
PE20121687A1 (es) 2012-12-14
LT2521536T (lt) 2018-10-10
US20190002574A1 (en) 2019-01-03
RU2554779C2 (ru) 2015-06-27
TW201617095A (zh) 2016-05-16
CY1121420T1 (el) 2020-05-29
UY33169A (es) 2011-08-31
CN102869346A (zh) 2013-01-09
EP2521536B9 (fr) 2018-12-12
DK4098247T3 (da) 2025-09-15
SI2521536T1 (sl) 2018-12-31
RU2012133970A (ru) 2014-02-20
SI3409269T1 (sl) 2020-10-30
EP2521536B1 (fr) 2018-08-01
PT2521536T (pt) 2018-11-06
CO6592078A2 (es) 2013-01-02
PT4098247T (pt) 2025-09-02
DK3409269T3 (da) 2020-09-28
SMT202500337T1 (it) 2025-11-10
FI4098247T3 (fi) 2025-09-30
US20210230283A1 (en) 2021-07-29
PL3756652T3 (pl) 2022-11-07
LT4098247T (lt) 2025-10-10
WO2011085158A2 (fr) 2011-07-14
JO3417B1 (ar) 2019-10-20

Similar Documents

Publication Publication Date Title
MA35904B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
MA35355B1 (fr) Formulations stabilisées contenant des anticorps anti-pcsk9
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
PH12013500672A1 (en) Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies
PH12019502123A1 (en) Stable antibody formulation
MY157772A (en) Antibody formulation
EP3941945A4 (fr) Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant
MA37645B1 (fr) Formulations stabilisées contenant des anticorps anti-dll4
MA62173B1 (fr) Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
PH12021552092A1 (en) Stabilized formulations containing anti-il-33 antibodies
TN2010000290A1 (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
PT1200088E (pt) Composicao contendo paracetamol e drotaverina
MA38501B1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation
CY1125584T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
MA34232B1 (fr) Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation
HK1122047A (en) Antagonist anti-cd40 antibody pharmaceutical compositions
MA38807A1 (fr) Anticorps anti-activine a et leurs utilisations